Search Details

Word: pravastatin (lookup in dictionary) (lookup stats)
Dates: during 1990-1999
Sort By: most recent first (reverse)


Usage:

...recognized the importance of the study, which showed that in men and women with normal and near normal cholesterol levels, treatment with Mevacor reduced the incidence of first coronary events such as heart attack or unstable angina 36%. Unfortunately, the article incorrectly cited the generic name of Mevacor as pravastatin. The correct generic name is lovastatin. JOHN BLOOMFIELD, Director, Public Affairs Merck & Co., Inc. West Point...

Author: /time Magazine | Title: Letters: Dec. 15, 1997 | 12/15/1997 | See Source »

...sweeping study, more than 6,600 people with average total cholesterol of 220--just above the optimal 200--were placed on a cholesterol-lowering regimen of diet and exercise. Additionally, half took daily doses of the cholesterol drug pravastatin, while the other half took a placebo. After five years, the group taking the real drug was 36% less likely to have suffered a first heart attack and 33% less likely to have needed coronary bypass or angioplasty. What's more, their bad LDLs had fallen 25% while their good HDLs had risen...

Author: /time Magazine | Title: MATTERS OF THE HEART | 11/24/1997 | See Source »

...results, though dramatic, have met with some skepticism. The study was funded by Merck & Co., which sells pravastatin under the name Mevacor. Regular Mevacor treatments can cost $1,200 a year, and with 8 million people in the U.S. having slightly elevated cholesterol, Merck could have a huge new market. For now, however, doctors are impressed, concluding that what's good for Merck could also be good for patients...

Author: /time Magazine | Title: MATTERS OF THE HEART | 11/24/1997 | See Source »

With the CARE study, Pravachol, the trade name of Pravastatin, becomes the first cholesterol-lowering medication to reduce the risk of stroke...

Author: NO WRITER ATTRIBUTED | Title: Study Finds Drug Reduces Risks of Stroke, Death | 10/8/1996 | See Source »

...CARE trial demonstrates that treatment with pravastatin can substantially reduce the burden of cardiovascular disease in patients with a history of heart attack," said Frank M. Sacks, the principal investigator of CARE and associate professor of medicine...

Author: NO WRITER ATTRIBUTED | Title: Study Finds Drug Reduces Risks of Stroke, Death | 10/8/1996 | See Source »

| 1 | 2 | Next